Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03819452
Other study ID # Fleifel002
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2018
Est. completion date January 25, 2019

Study information

Verified date January 2019
Source Abha International Private Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a registry for all patients admitted to hospital settings with Ischemic stroke in Mansoura University Hospital. The registry will capture patients' data, investigations and vitamin D level on admission. Follow-up is taking place using MODIFIED RANKIN SCALE


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date January 25, 2019
Est. primary completion date January 25, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Newly diagnosed ischemic stroke not older than 48 hours

Exclusion Criteria:

- Ischemic stroke due to accidents or any trauma

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Vitamin D Level
Vitamin D level is measured upon the presentation of the case with ischemic stroke

Locations

Country Name City State
Egypt Mansoura University Mansourah Dakahlia
Switzerland IQVIA Basel

Sponsors (2)

Lead Sponsor Collaborator
Abha International Private Hospital Mansoura University, Egypt

Countries where clinical trial is conducted

Egypt,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation of Vitamin D level and the Incidence of Ischemic Stroke Correlation Analyses between vitamin D and ischemic stroke will be applies On admission
Secondary impact of vitamin D on ischemic stroke in relationship with gender subgroup analyses per gender will be applied to check the difference of vitamin D On admission
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2